BGNE

BeiGene, Ltd.

153.07 USD
-1.62 (-1.05%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

BeiGene, Ltd. stock is down -8.55% since 30 days ago. The next earnings date is Jul 31, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 8 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 6 CALLs, 4 PUTs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
23 Apr 14:24 21 Jun, 2024 160.00 CALL 75 0
25 Apr 14:36 16 Aug, 2024 165.00 CALL 50 7
25 Apr 14:42 16 Aug, 2024 165.00 CALL 100 7
29 Apr 15:26 17 May, 2024 165.00 CALL 100 5
07 May 16:15 21 Jun, 2024 140.00 CALL 10 0
16 May 19:59 15 Nov, 2024 250.00 PUT 5 37
17 May 13:45 15 Nov, 2024 250.00 PUT 5 81
17 May 14:55 15 Nov, 2024 250.00 PUT 5 81
17 May 17:48 16 Aug, 2024 250.00 PUT 5 100
18 Jun 16:00 16 Aug, 2024 170.00 CALL 244 156

About BeiGene, Ltd.

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma. Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC)